Thus, despite the complexity of PPP2R2A deficiency in the regulation of oncogenic signaling and cancer therapy in the different types of cancer, its impact on the increased sensitivity to CHK1 inhibition in NSCLC and HGSOC appears to be similar. This evidence concerns the gene CHEK1 and cancer.